📣 VC round data is live. Check it out!

Outset Medical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Outset Medical and similar public comparables like Sera Prognostics, LENSAR, Spectral AI, Cumberland and more.

Outset Medical Overview

About Outset Medical

Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.


Founded

2003

HQ

United States

Employees

310

Financials (LTM)

Revenue: $122M
EBITDA: ($45M)

EV

$16M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Outset Medical Financials

Outset Medical reported last 12-month revenue of $122M and negative EBITDA of ($45M).

In the same LTM period, Outset Medical generated $50M in gross profit, ($45M) in EBITDA losses, and had net loss of ($73M).

Revenue (LTM)


Outset Medical P&L

In the most recent fiscal year, Outset Medical reported revenue of $120M and EBITDA of ($46M).

Outset Medical is unprofitable as of last fiscal year, with gross margin of 39%, EBITDA margin of (39%), and net margin of (68%).

See analyst estimates for Outset Medical
LTMLast FY202320242025202620272028
Revenue$122M$120M$130M$114M$119M
Gross Profit$50M$47M$29M$39M$47M
Gross Margin41%39%22%34%39%
EBITDA($45M)($46M)($154M)($98M)($63M)
EBITDA Margin(37%)(39%)(118%)(86%)(52%)
EBIT Margin(40%)(42%)(130%)(100%)(56%)
Net Profit($73M)($82M)($173M)($128M)($82M)
Net Margin(60%)(68%)(133%)(113%)(68%)
Net Debt$61M

Financial data powered by Morningstar, Inc.

Outset Medical Stock Performance

Outset Medical has current market cap of $71M, and enterprise value of $16M.

Market Cap Evolution


Outset Medical's stock price is $3.81.

Outset Medical share price decreased by 10.8% in the last 30 days, and by 78.3% in the last year.

Outset Medical has an EPS (earnings per share) of $-4.40.

See more trading valuation data for Outset Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$16M$71M-2.1%-10.8%9.2%-78.3%$-4.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Outset Medical Valuation Multiples

Outset Medical trades at 0.1x EV/Revenue multiple, and (0.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Outset Medical

EV / Revenue (LTM)


Outset Medical Financial Valuation Multiples

As of May 15, 2026, Outset Medical has market cap of $71M and EV of $16M.

Outset Medical has a P/E ratio of (1.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.1x0.1x0.1x0.1x0.1x
EV/EBITDA(0.3x)(0.3x)(0.1x)(0.2x)(0.2x)
EV/EBIT(0.3x)(0.3x)(0.1x)(0.1x)(0.2x)
EV/Gross Profit0.3x0.3x0.5x0.4x0.3x
P/E(1.0x)(0.9x)(0.4x)(0.6x)(0.9x)
EV/FCF(0.3x)(0.1x)(0.1x)(0.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Outset Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Outset Medical Margins & Growth Rates

Outset Medical grew revenue by 6% but EBITDA decreased by 8% in the last fiscal year.

In the most recent fiscal year, Outset Medical reported gross margin of 39%, EBITDA margin of (39%), and net margin of (68%).

See estimated margins and future growth rates for Outset Medical

Outset Medical Margins

Last FY202420252026202720282029
Gross Margin39%34%39%44%
EBITDA Margin(39%)(86%)(52%)(34%)
EBIT Margin(42%)(100%)(56%)(36%)
Net Margin(68%)(113%)(68%)(47%)
FCF Margin(39%)(103%)(39%)

Outset Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%(13%)5%6%
Gross Profit Growth19%33%21%19%
EBITDA Growth(8%)(36%)(36%)(32%)
EBIT Growth(9%)(33%)(41%)(31%)
Net Profit Growth(28%)(26%)(36%)(28%)
FCF Growth(13%)(60%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Outset Medical Operational KPIs

Outset Medical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Outset Medical's Rule of 40 is (28%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Outset Medical's Rule of X is (19%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Outset Medical
LTMLast FY202320242025202620272028
Rule of 40(29%)(28%)
Bessemer Rule of X(17%)(19%)
Revenue per Employee$0.4M
Opex per Employee$0.4M
S&M Expenses to Revenue42%45%74%62%45%
G&A Expenses to Revenue24%32%35%38%32%
R&D Expenses to Revenue15%18%44%34%18%
Opex to Revenue95%152%134%95%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Outset Medical Competitors

Outset Medical competitors include Sera Prognostics, LENSAR, Spectral AI, Cumberland, Klea, Creo Medical Group, Anatolia Geneworks, FluoGuide, Bactiguard and Xtant Medical.

Most Outset Medical public comparables operate across Medical Devices, Mental Health Technology, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sera Prognostics311.1x123.1x(0.8x)(0.7x)
LENSAR1.0x1.2x301.3x(92.6x)
Spectral AI3.4x3.4x(14.6x)
Cumberland1.6x24.4x
Klea3.5x15.4x
Creo Medical Group8.4x4.7x(1.5x)(2.6x)
Anatolia Geneworks4.6x(34.4x)
FluoGuide(10.6x)(9.6x)

This data is available for Pro users. Sign up to see all Outset Medical competitors and their valuation data.

Start Free Trial

Outset Medical Funding History

Before going public, Outset Medical raised $606M in total equity funding, across 5 rounds.


Outset Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-20Secondary - public$212MOutset Medical develops medical devices in dialysis technology. The company raised $132 million in its Series D funding round on February 5, 2020, led by investors including Mubadala Investment Company. Prior rounds included a Series C of $76.5 million and multiple undisclosed rounds totaling approximately $232.5 million, bringing cumulative funding to $538.3 million across seven rounds.
Feb-20Series ED1 Capital Partners; Fidelity; Partner Fund Management; T. Rowe Price$125MOutset Medical, a medtech company developing the Tablo Hemodialysis System, announced a $125 million Series E equity financing round on February 4, 2020, led by D1 Capital Partners with participation from Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, and funds advised by T. Rowe Price Associates. The Tablo system is an FDA-cleared, all-in-one dialysis machine designed for acute, chronic, and potentially home use, aiming to reduce costs and complexity in dialysis care using only tap water and electricity. The funding supports commercial expansion across U.S. acute and chronic care markets amid a $75 billion annual U.S. dialysis industry serving over 550,000 patients. CEO Leslie Trigg highlighted Tablo's intuitive design for improving patient experience and reducing costs, while D1 Capital founder Dan Sundheim emphasized its potential to disrupt the market, especially with growing focus on chronic kidney disease. The company had previously raised significant funding, including a $132 million Series D in 2018 with Baxter Ventures. Post-round, Outset Medical went public in September 2020, raising $242-278 million in an IPO valuing the company at over $1-2.47 billion, with major shareholders including Warburg Pincus (21%), Fidelity (11.1%), D1 Capital (9%), and T. Rowe Price (8.7%). The IPO proceeds funded sales, customer support, and R&D enhancements.
Aug-18Series DBaxter Ventures; Fidelity; Mubadala Capital Ventures; Partner Fund Management; Perceptive Advisors; T. Rowe Price; Warburg Pincus$132MOutset Medical, a San Jose, California-based commercial-stage medtech company, develops the Tablo Hemodialysis System, an all-in-one dialysis machine that simplifies treatment by integrating water purification, dialysate production, sensor-based automation, wireless data transmission, and a touchscreen interface. Tablo connects directly to tap water, eliminating the need for centralized water processing equipment, and is FDA-cleared for acute and chronic care settings, with potential for home use pending clinical trials. The system aims to reduce dialysis costs and complexity, expand treatment flexibility across various settings, and improve patient and provider experience while addressing a major global healthcare spend area. On August 28, 2018, Outset Medical closed a $132 million Series D equity financing round, led by new investor Mubadala Investment Company (noted as Mubadala Capital Ventures in query), with participation from existing investors Baxter Ventures, Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, funds advised by T. Rowe Price Associates, and Warburg Pincus. This followed prior rounds including a $60 million Series B, $76.5 million Series C for Tablo development and launch scaling, and a $4.3 million mixed financing in July prior to Series D. Proceeds from the $132 million round were allocated to increase production capabilities and accelerate U.S. commercial expansion of Tablo in acute and chronic care markets, supporting broader adoption to transform dialysis delivery. The company highlighted Tablo's disruptive potential in the growing global dialysis market, where it offers convenient, cost-effective alternatives to traditional systems.
May-17Series CFidelity; Partner Fund Management; Perceptive Advisors; T. Rowe Price; The Vertical Group; Warburg Pincus$77MOutset Medical develops the Tablo Hemodialysis System, an innovative all-in-one dialysis machine designed to simplify treatment, reduce costs, and expand usability across acute, chronic, and potentially home care settings. The Tablo system features sensor-based automation, wireless data transmission, touchscreen interface, and on-demand dialysis fluid generation from tap water, marking the first new U.S. dialysis system in over 15 years with FDA clearance for acute and chronic care and CE mark approval. In May 2017, Outset Medical raised $76.5 million in its Series C funding round led by funds advised by T. Rowe Price Associates, with participation from existing investors including Fidelity Management & Research Company, Partner Fund Management, Perceptive Advisors, The Vertical Group, and Warburg Pincus. The proceeds were allocated to support ongoing clinical trials, regulatory approvals, and the commercial introduction of the Tablo system in U.S. acute and chronic care markets, including dialysis clinics, hospitals, and skilled nursing facilities. At the time, the company was conducting an IDE trial to expand Tablo's indications to home use, positioning it as a flexible, self-serve solution to improve patient experience and lower infrastructure and labor costs in dialysis care. CEO Leslie Trigg highlighted the technology's potential to upgrade treatment and drive cost reductions in a labor-intensive sector. Subsequent rounds included a $132 million Series D in August 2018 led by Mubadala and a $125 million Series E in February 2020 led by D1 Capital with continued investor support.
May-15Series BThe Vertical Group; Warburg Pincus$60M

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Outset Medical

When was Outset Medical founded?Outset Medical was founded in 2003.
Where is Outset Medical headquartered?Outset Medical is headquartered in United States.
How many employees does Outset Medical have?As of today, Outset Medical has over 310 employees.
Who is the CEO of Outset Medical?Outset Medical's CEO is Leslie L. Trigg.
Is Outset Medical publicly listed?Yes, Outset Medical is a public company listed on Nasdaq.
What is the stock symbol of Outset Medical?Outset Medical trades under OM ticker.
When did Outset Medical go public?Outset Medical went public in 2020.
Who are competitors of Outset Medical?Outset Medical main competitors include Sera Prognostics, LENSAR, Spectral AI, Cumberland, Klea, Creo Medical Group, Anatolia Geneworks, FluoGuide, Bactiguard, Xtant Medical.
What is the current market cap of Outset Medical?Outset Medical's current market cap is $71M.
What is the current revenue of Outset Medical?Outset Medical's last 12 months revenue is $122M.
What is the current revenue growth of Outset Medical?Outset Medical revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Outset Medical?Current revenue multiple of Outset Medical is 0.1x.
Is Outset Medical profitable?No, Outset Medical is not profitable.
What is the current EBITDA of Outset Medical?Outset Medical has negative EBITDA and is not profitable.
What is Outset Medical's EBITDA margin?Outset Medical's last 12 months EBITDA margin is (37%).
What is the current EV/EBITDA multiple of Outset Medical?Current EBITDA multiple of Outset Medical is (0.3x).
How many companies Outset Medical has acquired to date?Outset Medical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Outset Medical has invested to date?Outset Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Outset Medical

Lists including Outset Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial